Researcher presents vexing information on rilpivirine.
Dalton
Paul
P
D035843:Biomedical Research; D018791:CD4 Lymphocyte Count; D017322:Clinical Trials, Phase II as Topic; D024882:Drug Resistance, Viral / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D009154:Mutation; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000068696:Rilpivirine; D019562:Viral Load
D009570:Nitriles; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; D000068696:Rilpivirine